SCHEMBL24766050

SCHEMBL24766050

CC(C)(C)OC(=O)n1cnc(-c2cc(Cl)cc(N3CCOCC3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 2/20 0.39
▸ USP2 O75604 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ KIF18A Q8NI77 2/20 0.37
▸ SUV39H2 Q9H5I1 1/20 0.37
▸ AKT1 P31749 2/20 0.36
▸ PIK3CA P42336 6/20 0.36
▸ PIK3R1 P27986 3/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ATRIP Q8WXE1 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24766049 0.80 ROCK2 (0.40) AKT1PIK3CAPIK3R1PIK3CDPIK3CB
SCHEMBL29434090 0.80 ROCK2 (0.40) AKT1PIK3CAPIK3R1PIK3CDPIK3CB
SCHEMBL24851269 0.72 USP2 (0.54) USP2SMN1; SMN2SUV39H2PIK3CAPIK3CD
SCHEMBL24312197 0.71 AKT1 (0.43) USP2KIF18ASUV39H2AKT1TSHR
SCHEMBL24312255 0.69 AKT1 (0.39) ATRSMN1; SMN2KIF18ASUV39H2AKT1
SCHEMBL18153347 0.69 PIK3CA (0.53) USP2SMN1; SMN2PIK3CAPIK3R1PIK3CD
SCHEMBL1497394 0.69 SMN1; SMN2 (0.49) USP2SMN1; SMN2SUV39H2AKT1PIK3CA
SCHEMBL29434915 0.69 PIK3CA (0.53) USP2SMN1; SMN2PIK3CAPIK3R1PIK3CD
SCHEMBL3997637 0.69 PIK3CA (0.53) USP2SMN1; SMN2PIK3CAPIK3R1PIK3CD
SCHEMBL21166287 0.68 AKT1 (0.43) USP2SMN1; SMN2AKT1PIK3CAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11407737-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-08-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11407737-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF ATR 493/4885USP2 1597/4885SMN1; SMN2 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback